Cystic fibrosis with chronic Pseudomonas aeruginosa infections(Phase 2)
Status note Dec 8, 2025: company announced discontinuation of the ongoing Phase 2b trial of BX004. BiomX Israel then commenced insolvency proceedings (Dec 2025; trustee appointed Jan 25, 2026; subsidiary deconsolidated Feb 4, 2026). Company has transitioned strategy to defense, security and critical-infrastructure technology (ZorroNet, DFSL acquisitions; X Security & Defense subsidiary) and no longer conducts pharmaceutical operations.
Per-asset detail extracted from the 10-Q filed 2026-08-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.